GSK RSV vaccine shows potential to protect adults 50 to 59

A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday.The initial trial results suggest that GSK's shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes...

Read more...

Sanofi to offer insulin for $35 to Americans through GoodRx

Sanofi Lantus brand insulin pens are arranged for a photograph in Brooklyn, New York, on April 5, 2019.Alex Flynn | Bloomberg | Getty ImagesAmericans, regardless of their insurance status, can now access Sanofi's most widely prescribed insulin for $35 through the prescription drug savings company GoodRx, the companies announced...

Read more...

Pfizer to price Covid drug Paxlovid at $1,390 per course

Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022.Wolfgang Rattay | ReutersPfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this...

Read more...

Incoming Walgreens CEO doesn’t mention pharmacy walkouts

Tim Wentworth, former CEO of Express Scripts.David A. Grogan | CNBCIncoming Walgreens CEO Tim Wentworth on Thursday briefly praised the company's pharmacy staff, but made no mention of the three-day protest walkouts they held this week over poor working conditions.The walkouts reflect rising dissatisfaction among pharmacy employees, who have...

Read more...

Novavax Covid vaccine can still catch up to Pfizer, Moderna shots

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.Patrick Van Katwijk | Getty ImagesAmericans can finally get their hands on Novavax's newest Covid vaccine after U.S. regulators greenlighted...

Read more...